5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Advanced Enzyme Technologies Ltd.

•
advancedenzymes.comBSE: 540025NSE: ADVENZYMES
Market Cap₹ 3,395 Cr.
Current Price
High / Low₹ 419 / 252
Stock P/E42.3
Book Value₹ 65
Price to Book4.08
Dividend Yield1.76 %
ROCE23.6 %
ROE19.9 %
Face Value₹ 2

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2022 • Human Nutrition: 71.5% • Bio-Process: 14.9% • Animal Nutrition: 13.6%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Company has a healthy return on capital (ROCE) of 22.6%
  • Company has been maintaining a healthy dividend payout of 45.4%
  • Company generates healthy free cash flow
  • Company has a consistent dividend-paying track record

CONS

  • Recent results are weak - TTM profit is down 56.8% versus prior year
  • A large part of profit comes from other income (40.8% of PBT)
  • Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.60x)
  • Recurring exceptional / one-off items are inflating headline profit

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY MICROCAP250NIFTY TOTAL MKT
S.No.Name
1.SUNPHARMA1864.0036.98447236.040.862901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9405.0085.36249673.200.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4928.4085.95187460.490.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1118.0024.71111520.930.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1380.0033.08111484.470.94785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1936.0095.67104604.450.10362.07123.942026.3129.1018.2031.50
7.AUROPHARMA1669.0025.8796030.570.241032.0325.229150.3517.4412.7620.54
8.DRREDDY1140.8029.5595220.280.70435.60-69.108099.80-5.2113.7510.63
9.LUPIN2075.0017.1694882.670.871416.9816.018276.8934.2828.8629.59
10.MANKIND2246.0045.4292769.930.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2417.0037.9468213.700.10482.83927.884018.4831.3520.3520.03
12.ADVENZYMES303.1520.463394.561.7638.59-4.58189.792.0915.2726.85
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
8597919286771018712511696116116
61706763656479739486729088
Operating Profit25272529211422143130232727
OPM %29.03%27.56%26.94%31.65%24.34%17.49%21.87%16.25%24.41%25.56%24.54%23.07%23.70%
5114-1654215543-352
Interest0000000000000
Depreciation3333333333333
Profit before Tax73252510721221168130182930
Tax %8.17%25.77%24.61%69.78%7.07%25.97%26.10%28.76%9.12%24.78%25.65%22.71%24.86%
Net Profit671819367915117422132222
6.041.641.710.286.000.821.350.996.611.991.181.992.00

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
173212222247283273312365351453444
124163169170183200236260280343336
Operating Profit49495377101737510571110107
OPM %28.09%23.30%23.81%31.11%35.58%26.70%24.10%28.81%20.19%24.25%24.20%
666979104061608
Interest33310000100
Depreciation88999101011111212
Profit before Tax44444776987274134121158106
Tax %20.81%18.14%25.36%23.60%27.85%24.37%25.24%19.31%15.02%16.41%24.39%
Net Profit3536355871555610810213280
EPS3.123.213.155.186.354.874.979.679.1511.78—
Dividend Payout %12.92%15.55%19.01%11.56%14.16%20.51%20.14%52.75%56.80%45.43%—

COMPOUNDED SALES GROWTH

10 Years:
13%
5 Years:
10%
3 Years:
13%

COMPOUNDED PROFIT GROWTH

10 Years:
20%
5 Years:
13%
3 Years:
33%

STOCK PRICE CAGR

10 Years:
0%
5 Years:
-4%
3 Years:
-2%
1 Year:
-14%

RETURN ON EQUITY

10 Years:
16%
5 Years:
16%
3 Years:
19%
Last Year:
20%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Aug 13

₹ 478.50

Bord Resolution for the Buyback

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital22222222222222222222
233264294345410457503555602678
3340189111121
Trade Payables8211614232018222551
21252633342931333751
Total Liabilities318373376423490530576633689804
989897127132132143142156151
Capital Work in Progress1215236162149
103120120121184189201256290345
5155596063807797101117
0000000757894
Cash & Bank101321825262
639798108106107124443646
Total Assets318373376423490530576633689804

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
313148591115967526389
Cash from Investing-55-22-2-25-70-14-42-3-2-34
Cash from Financing34-1-33-19-15-11-12-57-58-58
-0-0-02-112-4-84-4

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
43.0242.9542.9343.0843.0843.0743.0443.2643.24
12.0312.6312.5811.9023.4525.4125.8525.5026.70
8.088.028.178.198.456.415.515.414.77
Government0.000.000.000.000.000.000.000.000.00
36.8836.4136.3236.8325.0225.1025.6025.8425.27

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-10
Copy of Newspaper Publication

2026-09-10 - Advanced Enzyme Technologies Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-08
Updates

2026-09-08 - Advanced Enzyme Technologies Limited has informed the Exchange regarding 'Extinguishment of Equity Shares'.

2026-09-05
General Updates

2026-09-05 - Intimation of receipt of request from a few promoter group members for reclassification from Promoter Group category to Public category shareholders under Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

2026-08-18
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-18 - Advanced Enzyme Technologies Limited has informed the Exchange about Transcript

2026-08-13
General Updates

2026-08-13 - Advanced Enzyme Technologies Limited has informed the Exchange about General Updates

2026-08-12
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-12 - Advanced Enzyme Technologies Limited has informed the Exchange about Link of Recording

2026-08-11
Buyback

2026-08-11 - Advanced Enzyme Technologies Limited has submitted the Exchange the Board Resolution of Buyback

2026-08-11
Public Announcement - Buyback of Shares

2026-08-11 - Advanced Enzyme Technologies Limited has informed the Exchange about public Announcement - Buyback of Shares

2026-08-10
Copy of Newspaper Publication

2026-08-10 - Advanced Enzyme Technologies Limited has informed the Exchange about Copy of Newspaper Publication

News

Recent coverage and analyst commentary for ADVENZYMES

Loading news…

🤖

AI Stock Analyst

Advanced Enzyme Technologies Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login